tomeko

Mucopolysaccharidosis type 2, severe form

Just diagnosed with Mucopolysaccharidosis type 2, severe form?

You are not alone. Here is where to start: learn the basics, find a specialist or center that sees Mucopolysaccharidosis type 2, severe form, look for clinical trials, and connect with others living with it — all in one place.

Open the full Mucopolysaccharidosis type 2, severe form hub →

Overview

Mucopolysaccharidosis type 2, severe form is a rare condition. Also known as Hunter syndrome type A, Iduronate 2-sulfatase deficiency type A, MPS2A, MPSIIA, Mucopolysaccharidosis type 2, early progressive form, Mucopolysaccharidosis type 2, neuropathic form, Mucopolysaccharidosis type 2A, Mucopolysaccharidosis type II, severe form. Tomeko brings together the specialists, research, clinical trials, treatments and community for Mucopolysaccharidosis type 2, severe form so you can go from overwhelmed to oriented. For authoritative medical detail, see the reference sources below.

Identifiers: ORPHA:217085 · OMIM 309900 · ICD-10 E76.1 · GARD 0017118

Find care for Mucopolysaccharidosis type 2, severe form

Authoritative references for Mucopolysaccharidosis type 2, severe form

Common questions

I was just diagnosed with Mucopolysaccharidosis type 2, severe form — what should I do first?

Start by learning the basics from an authoritative source, find a specialist or center that sees Mucopolysaccharidosis type 2, severe form, and connect with a patient organization. Tomeko brings these together on one hub.

Where can I find a specialist for Mucopolysaccharidosis type 2, severe form?

Use Tomeko's specialist and Centers-of-Excellence directories to find clinicians who treat Mucopolysaccharidosis type 2, severe form, filtered to your area.

Are there clinical trials for Mucopolysaccharidosis type 2, severe form?

Tomeko shows live, recruiting studies for Mucopolysaccharidosis type 2, severe form from ClinicalTrials.gov on the hub.

Informational only — not medical advice. Always consult a qualified clinician. Provider and reference data from public sources (NIH GARD, Orphanet, OMIM, HPO, MONDO, ClinicalTrials.gov, CMS NPPES). © Tomeko · tomekohealth.com